Taking people in FrancePhase 1
Testing REGN5837 with odronextamab for aggressive B-cell lymphomas
Tests whether REGN5837 with odronextamab is safe in adults with aggressive B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas
Key facts
- Where
- Paris, Pessac, and Villejuif, FranceSee the 3 sites
- Phase
- Phase 1
Where in France
- Hopital Saint LouisParis, FranceTaking people
- Centre Hospitalier Universitaire de BordeauxPessac, FranceTaking people
- Institut Gustave RoussyVillejuif, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals Inc.
- Trial code
- NCT05685173EU 2022-502137-26-00
- Record updated
- 3 August 2026